Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.555 USD | -3.58% | -11.09% | +88.43% |
May. 07 | Transcript : Trevi Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 187M |
---|---|---|---|---|---|
Net income 2024 * | -43M | Net income 2025 * | -53M | EV / Sales 2024 * | - |
Net cash position 2024 * | 107M | Net cash position 2025 * | 188M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.2
x | P/E ratio 2025 * |
-5.76
x | Employees | 25 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.74% |
Latest transcript on Trevi Therapeutics, Inc.
1 week | -7.04% | ||
Current month | -9.90% | ||
1 month | -7.37% | ||
3 months | +6.02% | ||
6 months | +129.57% | ||
Current year | +97.01% |
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Good
FOU | Founder | 59 | 11-02-28 |
Thomas Sciascia
FOU | Founder | 70 | 10-12-31 |
Lisa Delfini
DFI | Director of Finance/CFO | 54 | 21-08-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anne VanLent
BRD | Director/Board Member | 76 | 18-10-09 |
James Cassella
BRD | Director/Board Member | 69 | 20-02-12 |
Jennifer Good
FOU | Founder | 59 | 11-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +4.06% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 2.525 | -4.72% | 56 790 |
24-05-22 | 2.65 | -2.93% | 81,546 |
24-05-21 | 2.73 | -3.53% | 95,788 |
24-05-20 | 2.83 | +2.17% | 147,690 |
24-05-17 | 2.77 | -2.46% | 66,965 |
Delayed Quote Nasdaq, May 23, 2024 at 11:20 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+97.01% | 187M | |
+10.52% | 115B | |
+12.77% | 106B | |
-4.65% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-11.19% | 17.56B | |
-39.36% | 17.32B | |
+6.62% | 14.03B | |
+32.54% | 12.13B |
- Stock Market
- Equities
- TRVI Stock